Compare Bristol-Myers Squibb Co (BMY) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Kaltura Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.91 (market cap $129.94B), while Kaltura Inc trades at $1.59 (market cap $249.42M). The key difference: Bristol-Myers Squibb Co is far larger — about 521× Kaltura Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| BMY | KLTR | |
|---|---|---|
Market Cap | $129.94B | $249.42M |
Sector | Health | Technology |
52-Week High | $65.89 | $1.89 |
52-Week Low | $42.60 | $1.08 |
Enterprise Value | $163.92B | $261.64M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Kaltura (KLTR) trades at $1.61, down 1.83% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported Q2 2026 earnings that beat expectations, with revenue stable around $181 million and improving net loss margins. Recent news highlights leadership in virtual event platforms and AI technology awards, alongside significant insider selling in August 2026.
The outlook is mixed: analyst consensus leans buy (44.45%) with strong gross margins (72.05%), but persistent net losses and high valuation ratios (EV/EBITDA 336.29) pose risks. Investment opportunity hinges on AI product growth and cost management, while execution risks and cash flow volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
